We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


JHL Biotech and Affinita Biotech Agree to Partner

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

JHL Biotech, Inc. has announced it has entered into a contract manufacturing master service agreement with Affinita Biotech. The agreement covers a development and manufacturing partnership for Affinita’s oncology monoclonal antibodies.

The agreement, extending to 2020, is estimated to be worth up to US$20 million in value. JHL will
provide cell line development, process development, and manufacturing expertise. The activities will
be carried out in JHL's Zhubei site in Taiwan as well as at JHL’s manufacturing facility in Wuhan,